Cost-Saving Growth Driven by NHS, Patent Expiry & New Launches Drive Market Growth

UK generic drug market was valued at $28.2 billion in 2024 and is projected to reach $52.8 billion by 2035, growing at a CAGR of 5.8% during the forecast period (2025–2035). The healthcare system drives the UK generic market, prioritizing affordability and accessibility. Most of the patents on widely used drugs have expired, and generic versions are available, offering patients the same therapeutic benefit at lower cost. Competing manufacturers offering competitive prices and good production quality have increased trust among providers and patients correspondingly. Continued pressure for manageable healthcare costs continues to stimulate the trend toward generics. Additionally, regulatory alignment and effective approval procedures have expedited product release into the marketplace.

Browse the full report description of “UK Generic Drug Market Size, Share & Trends Analysis Report by Route of Administration (Oral, Topical, Injectable, and Inhaler), and by Application (Cancer, CVD, Musculoskeletal, Infectious Diseases, Neurology, Diabetes, and Others), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/uk-generic-drugs-market

According to the British Generic Manufacturers Association, in August 2025, there were 3,603 various generic medicine presentations featured in the Drug Tariff, with some shortages being tracked by Medicines UK and NHS organizations.

The UK generic medicines market is firmly established, fueled by the NHS's emphasis on cost-saving prescribing and expiration of patents for many branded medicines. Rising demand for cheap medicines continues to consolidate the position of local and multinational producers. For instance, Accord Healthcare Ltd. provides a diverse range of portfolio of generic prescription medicines across therapeutic categories in the UK.

Key Market Developments

• In June 2025, Indoco Remedies UK Ltd. introduced Ticagrelor film-coated tablets 90mg in the UK. This significant expansion to Indoco’s portfolio, marketed and distributed by Clarity Pharma across the UK. Ticagrelor film-coated tablets are indicated to lower the risk of heart attack, stroke, myocardial infarction (MI), and other disorders linked to the heart or blood vessels.

• In February 2025, Biocon Ltd. introduced its Glucagon-like peptide-1 (GLP-1), Liraglutide, in the UK. The launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the UK. The drug-device combination will be marketed in the UK under the brand names Liraglutide Biocon for diabetes (gVictoza) and Biolide for chronic weight management (gSaxenda). The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., earlier this year.

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Route of Administration

o By Application

• Competitive Landscape - AstraZeneca, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Sandoz Group AG (a division of Novartis), and Viatris Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

UK Generic Drugs Market Report Segment

By Route of Administration

• Oral
• Topical
• Injectable
• Inhaler

By Application

• Cancer
• CVD
• Musculoskeletal 
• Infectious Diseases
• Neurology
• Diabetes
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-generic-drugs-market